Report of Foreign Issuer (6-k)
September 01 2020 - 10:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
September 2020
Commission file number: 001-36288
Akari Therapeutics, Plc
(Translation of registrant's name into English)
75/76 Wimpole Street
London W1G 9RT
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form
40-F ¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ¨
CONTENTS
On September 1,
2020, Akari Therapeutics, Plc (the “Company”) issued unaudited interim condensed consolidated financial
statements as of June 30, 2020, prepared in accordance with generally accepted accounting principles in the United States,
together with the Company’s Management Discussion and Analysis of Financial Condition and Results of Operations for the
same period. Attached hereto and incorporated by reference herein are the following exhibits:
In addition, on
September 1, 2020, the Company issued a press release announcing its second quarter 2020 financial results and recent
clinical progress highlights. A copy of the press release is attached hereto as Exhibit 99.3 and incorporated herein by
reference.
The information contained
in Exhibits 99.1 and 99.2 and the statements under “Second Quarter 2020 Financial Results”, the accompanying financial
statements and “Cautionary Note Regarding Forward-Looking Statements” of Exhibit 99.3 are hereby incorporated by reference
into all effective registration statements filed by the Company under the Securities Act of 1933.
Exhibit No.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Akari Therapeutics, Plc
|
|
(Registrant)
|
|
|
|
|
By:
|
/s/ Clive Richardson
|
|
Name:
|
Clive Richardson
|
|
|
Chief Executive Officer and Chief Operating Officer
|
Date: September 1, 2020
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Sep 2023 to Sep 2024